Non-alcoholic Steatohepatitis Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others), By End User (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes), By Region and Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 1.94 Billion
CAGR (2026-2031)	23.34%
Fastest Growing Segment	Hepatic Fibrosis Biomarkers
Largest Market	North America
Market Size (2031)	USD 6.83 Billion

Market Overview

The Global Non-alcoholic Steatohepatitis Biomarkers Market is projected to grow from USD 1.94 Billion in 2025 to USD 6.83 Billion by 2031 at a 23.34% CAGR. Non-alcoholic Steatohepatitis (NASH) biomarkers are measurable biological indicators employed for the diagnosis, prognosis, and monitoring of NASH, a severe form of fatty liver disease. The market's expansion is significantly driven by the increasing global incidence of metabolic disorders contributing to NASH, the imperative for non-invasive diagnostic tools to replace invasive liver biopsies, and growing pharmaceutical research into NASH therapeutics. According to the American Liver Foundation, as of March 2026, between 1.5% and 6.5% of adults in the United States are estimated to have metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.

This considerable patient population underscores the urgent need for effective diagnostic and monitoring solutions. However, a primary challenge impeding market growth remains the protracted and complex process of validating new biomarkers to meet stringent regulatory requirements, coupled with the absence of widely adopted standardized protocols for their clinical application.

Key Market Drivers

Rising prevalence and at-risk population driving biomarker demand
The rising global prevalence of non-alcoholic steatohepatitis (NASH), obesity, and type 2 diabetes significantly propels the Non-alcoholic Steatohepatitis Biomarkers Market. These interconnected metabolic disorders create a substantial patient pool requiring advanced diagnostic and monitoring tools, thereby increasing the demand for accurate and non-invasive biomarkers. The International Diabetes Federation's (IDF) Diabetes Atlas 2025 reports that 11.1% of the adult population (20-79 years) is living with diabetes globally, underscoring the widespread presence of a major risk factor for NASH development. This growing patient demographic necessitates efficient screening and diagnostic solutions to identify individuals at risk or in early stages of NASH progression.

R&D investments in NASH therapies and biomarkers
Increased research and development investments in NASH therapies and biomarkers further drive market expansion. Pharmaceutical companies and biotechnology firms are actively funding the discovery and validation of novel biomarkers to support drug development, patient stratification for clinical trials, and treatment monitoring. According to Fidelity Investments, in November 2025, pharmaceutical investment in late-stage MASH R&D is projected to exceed USD 30 billion between 2025 and 2033, indicating robust commitment to addressing this unmet medical need. Concurrently, regulatory milestones are accelerating the adoption of new diagnostic approaches; Fortrea, a clinical research organization, noted on August 27, 2025, that the FDA accepted a letter of intent for a non-invasive biomarker to be considered a surrogate endpoint reasonably likely to be associated with mortality and liver outcomes, streamlining the path for new biomarker approval and integration into clinical practice.

Download Free Sample Report

Key Market Challenges

The protracted and complex process of validating new biomarkers to meet stringent regulatory requirements, coupled with the absence of widely adopted standardized protocols for their clinical application, significantly impedes the growth of the global Non-alcoholic Steatohepatitis biomarkers market. This challenge creates substantial delays in bringing novel diagnostic tools to market. The rigorous evidence required for regulatory approval demands extensive clinical trials, increasing development costs and extending timelines, which deters investment and innovation. Furthermore, without standardized protocols, healthcare providers face uncertainty regarding the consistent and reliable application of new biomarkers, leading to hesitant adoption in routine clinical practice. This directly restricts the market's expansion by limiting the volume of commercially available and widely utilized diagnostic solutions.

This diagnostic gap is evident in real-world data. According to findings presented at the European Association for the Study of the Liver (EASL) Congress in 2025, results from the LIVERSCREEN cohort involving 30,541 participants indicated that from the 8% referred to hospitals, only 32% received a diagnosis of chronic liver disease with fibrosis, representing 782 individuals. This underscores a considerable challenge in identifying patients who could benefit from early intervention, a challenge that robustly validated and standardized non-invasive biomarkers would address, thereby unlocking a larger market for advanced detection and monitoring solutions.

Key Market Trends

The Global Non-alcoholic Steatohepatitis Biomarkers Market is notably shaped by the development of novel non-invasive biomarker tests. This trend is driven by the urgent need to move away from invasive liver biopsies, offering more patient-friendly and scalable diagnostic and monitoring solutions. The advancements in these tests, including imaging and blood-based assays, are improving early detection and patient stratification for therapeutic interventions. For instance, according to an article on openPR.com, in May 2026, Madrigal Pharmaceuticals signed a licensing deal worth up to $1 billion with Arrowhead Pharmaceuticals to strengthen its MASH/NAFLD pipeline, indicating substantial investment in diagnostic and therapeutic advancements.

Concurrently, a growing emphasis on hepatic fibrosis biomarkers for disease severity assessment represents another pivotal trend. These specific biomarkers are increasingly vital for accurately staging liver damage and fibrosis progression, which is crucial for determining treatment pathways and monitoring therapeutic efficacy. As pharmaceutical companies advance drug candidates, the utility of these biomarkers in clinical trials for evaluating treatment response is expanding. According to Gastroenterology & Hepatology, in December 2025, findings presented at the American Association for the Study of Liver Diseases 2025 Liver Meeting showed a mean change from baseline in PRO-C3 of -20.1% in a study evaluating resmetirom, highlighting its role as a validated marker of fibrosis.

Segmental Insights

The Hepatic Fibrosis Biomarkers segment is experiencing rapid growth within the Global Non-alcoholic Steatohepatitis Biomarkers Market due to its critical role in evaluating the severity and progression of liver damage. As non-alcoholic steatohepatitis (NASH) cases continue to rise globally, driven by factors like increasing obesity and type 2 diabetes, there is a heightened demand for precise tools to assess fibrosis, a key indicator of disease advancement. These biomarkers offer essential insights for clinicians in determining disease stage and informing treatment strategies, reducing reliance on invasive procedures like liver biopsy and supporting enhanced patient management.

Regional Insights

North America maintains its leading position in the Global Non-alcoholic Steatohepatitis Biomarkers Market. This dominance stems from a confluence of factors, including the region's highly developed healthcare infrastructure and substantial investments in research and development. The high prevalence of NASH, driven by rising rates of obesity and metabolic disorders, creates a significant demand for advanced diagnostic solutions. Additionally, supportive regulatory frameworks, particularly from the U.S. Food and Drug Administration, actively encourage the innovation and adoption of new biomarker technologies, thus accelerating market growth and the availability of effective disease management tools.

Recent Developments

• In December 2025, the FDA qualified AIM-NASH, an artificial intelligence-based drug development tool created by PathAI. This marks the first AI-based system to assist pathologists in evaluating metabolic dysfunction-associated steatohepatitis (MASH) disease activity in clinical trials. AIM-NASH analyzes liver biopsy components such as steatosis, inflammation, and fibrosis stage, complementing the current consensus reading process. The qualification of this tool is anticipated to streamline MASH trial processes, potentially reducing the time and resources needed for developing new therapies and improving the standardization of biomarker analysis.
• In August 2025, the U.S. Food and Drug Administration considered using a noninvasive liver measurement, specifically liver stiffness measured by transient elastography, as a surrogate endpoint for certain metabolic dysfunction-associated steatohepatitis (MASH) patients with moderate to advanced fibrosis. Echosens submitted the letter of intent to qualify this endpoint, with support from pharmaceutical companies including Eli Lilly, Boehringer Ingelheim, and Novo Nordisk. This development could accelerate drug development in the MASH space by offering a safer and more accessible method to monitor disease progression and treatment responses, potentially reducing reliance on invasive liver biopsies.
• In May 2025, Galmed Pharmaceuticals Ltd. announced the discovery of a proprietary pharmacodynamic (PD) blood-based biomarker signature for its lead candidate, Aramchol. This signature, derived from plasma samples during the Phase 3 ARMOR study for MASH/NASH, offered critical insights into Aramchol's multi-system therapeutic potential. The newly characterized biomarker profile confirmed on-target biological activity and suggested broader disease-modifying capabilities beyond initial liver-focused applications, extending into cardiometabolic and inflammatory conditions. This breakthrough highlights an advancement in understanding treatment responses through specific biomarkers within the global non-alcoholic steatohepatitis biomarkers market.
• In May 2025, PharmaNest introduced FibroMAP, which is positioned as the first single-fiber phenotypic tool designed for the study of fibrosis across various biological models and indications. This new product launch provides an advanced solution for evaluating fibrosis, a key pathological feature in the progression of Non-alcoholic Steatohepatitis. The availability of such a specialized tool is expected to significantly enhance research and diagnostic capabilities within the global non-alcoholic steatohepatitis biomarkers market by offering detailed insights into tissue remodeling and disease progression.

Key Market Players

• GENFIT SA
• Prometheus Laboratories Inc.
• Siemens Healthineers AG
• BioPredictive S.A.S.
• Quest Diagnostics Incorporated
• AstraZeneca PLC
• Meridian Bioscience, Inc.
• Laboratory Corporation of America Holdings
• Pfizer Inc.
• Bristol-Myers Squibb Company

By Type	By End User	By Region
Serum Biomarkers Hepatic Fibrosis Biomarkers Apoptosis Biomarkers Oxidative Stress Biomarkers Others	Pharma & CRO Industry Hospitals Diagnostic Labs Academic Research Institutes	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Non-alcoholic Steatohepatitis Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-alcoholic Steatohepatitis Biomarkers Market, By Type:

• Serum Biomarkers
• Hepatic Fibrosis Biomarkers
• Apoptosis Biomarkers
• Oxidative Stress Biomarkers
• Others

• Non-alcoholic Steatohepatitis Biomarkers Market, By End User:

• Pharma & CRO Industry
• Hospitals
• Diagnostic Labs
• Academic Research Institutes

• Non-alcoholic Steatohepatitis Biomarkers Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE